![]() |
Home | Contact Us | Site Map. |
||
Kytogenics represents an attractive, late stage investment opportunity. During the next 2 years the Company intends to bring to market six products in important therapeutic areas to include: NOCC™ Hydrophilic Wound Dressing Lubricants for Transurethral Surgical Instruments KYTO filed this 510K premarket notification for its solution-based product to be used as an aid in the insertion of transurethral surgical instruments. Super-Absorbent Wound Dressing KYTO has filed a 510K for its NOCC-based super absorbent gels for the development of haemostatic bandages. KYTO has developed NOCC-based super-absorbent gels that absorb 98X their weight of fluid demonstrating their potential as hemostats. Hemostatic Particles This 510K filed with the FDA for NOCC Hemostatic particles is used for leg ulcers, pressure ulcers and surgical wounds to provide moist wound healing and allow non-traumatic removal of the dressing. The dressing incorporates high wound exudate absorbing chitosan based powders, similar to those used in the Kytogenics Super-Absorbent Wound Dressing. There are two additional 510K applications being prepared that pertain to the indications shown below. These 510K applications are expected to be filed in Q2 2008. The Company expects to file additional 510K applications later 2008 which will include Absorbable Tendon Wraps and Cardiovascular Wraps. Ear Nose & Throat (ENT) Lubricants and Adjuncts to Protect Tissues and Promote Healing Dura-Wraps
|
|||
Copyright © 2004-2009 Kytogenics Pharmaceuticals, Inc. All rights reserved. |
|||